Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | -10.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.22 | N/A | -10.00% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about future opportunities despite the current challenges. They reiterated their focus on innovation.
Management noted ongoing challenges but emphasized commitment to long-term growth.
They highlighted the importance of innovation in their product pipeline.
The earnings report indicates that 10X Genomics faced challenges this quarter, particularly reflected in their EPS miss. The stock reacted with a slight decline of 1.04%, suggesting that investors were not overly surprised by the results. Management's cautious optimism may provide some reassurance, but the lack of revenue details leaves uncertainty about the company's immediate future.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EXELON CORP
May 8, 2020